Product Code: RP-ID-10151846 |
Published Date: 21 Oct 2022 |
Region: NA |
Category: Healthcare & Pharmaceuticals |
Report ID: 10151846
Market Overview:
Global Frontotemporal Disorders Treatment Industry Market Research 2022-2030
"The research-based frontotemporal disease treatment market is expected to grow at a compound annual growth rate of nearly 8% during the forecast period 2022-2030. And non-governmental organizations. The increasing prevalence of target diseases and the increasing number of elderly people suffering from these diseases are expected to promote market growth.
According to the World Health Organization, approximately 50 million people suffer from dementia, and there are approximately 10 million new cases each year, which is expected to drive the growth of the industry. Promote the development of this industry. Several organizations participating in this event include the National Institutes of Health (NIH), Alzheimer's Association, and the National Institute on Aging. In 2019, the National Institutes of Health spent approximately $387 million on Alzheimer;s disease-related dementia (ADRD) research projects. These measures are expected to provide growth opportunities for this market. However, the lack of awareness of target diseases in developing countries may limit the market.
Main market trends:
Antidepressants show profitable opportunities in the global frontotemporal disorder treatment market Antidepressants are used to treat major depression and other diseases, such as dysthymia, anxiety, obsessive-compulsive disorder (OCD), diet Disorders, chronic pain, neuropathy. Pain, etc. In October 2018, Lingbei launched Brintellix tablets in India for the treatment of major depression.
Similarly, in April 2019, Lupin launched fluoxetine antidepressant pills in the US market. The tablet is suitable for the treatment of severe depression and obsessive-compulsive disorder. Therefore, due to the increase in the number of patients and the recent product launches, the global market is expected to experience rapid growth during the forecast period.
North America dominates the global frontotemporal lobe disease treatment market:
As developed countries (such as the United States) have advanced healthcare facilities and infrastructure, North America is driven by high purchasing power of expensive drugs, policy reimbursements, and increase in the number of patients with estimated revenue dominating. Factors According to data from the National Institute of Neurological Diseases and Stroke, Alzheimer's disease alone, as a type of dementia, affects more than 5 million people in the United States. As the population ages, this disease will increase.
This helps supplement regional growth. Due to the increase in disposable income levels, the Asia-Pacific region is expected to achieve the fastest growth during the forecast period. In addition, due to the growing base of the elderly population and the weakened immune system, the high prevalence of target diseases is attributed to the growth of the industry.
Competitive landscape:
The frontotemporal lobe disease treatment market competes with some major players. Apotex Inc., AstraZeneca plc., Auro Pharma, Johnson & Johnson, Mylan N.V., Pfizer Inc., Sanofi S.A., Teva Pharmaceuticals USA, Inc. and other companies have a considerable market share in the market. In the next few years, other players are expected to enter the market.
Major Players
Johnson & Johnson
Apotex Inc.
Auro Pharma
Pfizer Inc.
Teva Pharmaceuticals USA, Inc."
Related Reports
Proof of Quality & Reliability
